FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Arxxant Japanese Development Ended

[ Price : $8.95]

Takeda and Lilly have ended an agreement to develop and market Lillys Arxxant in Japan.

FDA Approves Acromegaly Drug

[ Price : $8.95]

FDA approves Beaufour Ipsens Somatuline Depot for treating acromegaly.

AZ, Abbott Developing Statin/Fibrate Combination

[ Price : $8.95]

AstraZeneca and Abbott say they will proceed to Phase 3 trials with a Crestor/fibrate combination drug to target all three major b...

FDA Reviewers Back Merck HIV Drug

[ Price : $8.95]

In advance of a 9/5 panel meeting, FDA reviewers say Mercks experimental HIV-1 drug Isentress has shown antiviral activity and is ...

FDA OKs Caracos Generic Zyloprim

[ Price : $8.95]

FDA approves a Caraco Pharmaceutical Laboratories ANDA for a generic copy of Prometheus Laboratories Zyloprim.

Comments Sought on Symbols in IVD Labeling

[ Price : $8.95]

Federal Register Notice: FDA seeks comments on reporting requirements for a glossary and educational outreach to support use of sy...

Import Safety Group Plans Public Meeting

[ Price : $8.95]

Federal Register Notice: The Interagency Working Group on Import Safety plans a public meeting 10/1 to identify actions to promote...

Aussie Court Upholds Xenical Ad Ban

[ Price : $8.95]

Roche says it may not be able to continue supporting Xenical in Australia after a judge there upholds an advertising ban.

Phase 3 Trial for New ED Drug Delayed

[ Price : $8.95]

Palatin Technologies and King Pharmaceuticals say they are delaying Phase 3 trials for bremelanotide due to FDA efficacy concerns.

FDA Extends Review of Vernakalant NDA

[ Price : $8.95]

FDA extends by three months its review of a Cardiome Pharma and Astellas NDA on an intravenous formulation of vernakalant hydrochl...